CNR1
CNR1 Overview
| English Name | Cannabinoid CB1 receptor | Approved Drugs | 2 |
| Drugs in Clinical Trials | 38 | Target Synonym | Cannabinoid Receptor 1 (Brain)，CNR1，Cannabinoid Receptor 1，CANN6，CB-R，CNR，CB1，Central Cannabinoid Receptor，CB1K5，CB1A，CB1R，Receptor， Cannabinoid， CB1 |
| Highest Development Stage | Approved | ||
| English Name | Cannabinoid CB1 receptor |
| Target Synonym | Cannabinoid Receptor 1 (Brain)，CNR1，Cannabinoid Receptor 1，CANN6，CB-R，CNR，CB1，Central Cannabinoid Receptor，CB1K5，CB1A，CB1R，Receptor， Cannabinoid， CB1 |
| Approved Drugs | 2 |
| Drugs in Clinical Trials | 38 |
| Highest Development Stage | Approved |
CNR1 Product List
- Product Category
Protein (3)
- Product Status
Launched (3)
- Species
Human (3)
- Tag
- (1)His Tag & Flag Tag (1)His Tag & Avi Tag & Flag Tag (1)
- Conjugate
Unconjugated (2)Biotin-labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
 Human | HEK293 | Human CNR1 Full Length Protein (VLP) |  | |||
| Human | InsectCells | Human CNR1 Protein, Flag,His Tag (Detergent) |  |  | | |
| Human | InsectCells | Biotinylated Human CNR1 Protein, Flag Tag&His,Avitag™ (Detergent) |  | | |
Total: 3
- 1
CNR1 Background
This gene encodes one of two cannabinoid receptors. The cannabinoids, principally delta-9-tetrahydrocannabinol and synthetic analogs, are psychoactive ingredients of marijuana. The cannabinoid receptors are members of the guanine-nucleotide-binding protein (G-protein) coupled receptor family, which inhibit adenylate cyclase activity in a dose-dependent, stereoselective and pertussis toxin-sensitive manner. The two receptors have been found to be involved in the cannabinoid-induced CNS effects (including alterations in mood and cognition) experienced by users of marijuana. Multiple transcript variants encoding two different protein isoforms have been described for this gene.
CNR1 Synonyms
CNR1,cannabinoid receptor 1,CANN6, CB-R, CB1, CB1A, CB1K5, CB1R, CNR
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Dronabinol(AXIM Biotechnologies) | Phase 3 Clinical | Axim Biotechnologies Inc | Anorexia Nervosa; Cachexia; Child Nutrition Disorders; Nausea; Neoplasms; Nutrition Disorders; Sarcopenia; Vomiting | Details | |
| Cannabidiol soft-gel (Avecho Biotechnology) | CBD-TPM | Phase 3 Clinical | Avecho Biotechnology Ltd | Sleep Initiation and Maintenance Disorders | Details |
| Cannabidiol Gel (Zynerba) | ZYN002; ZYN-002 | Phase 3 Clinical | Zynerba Pharmaceuticals Inc | DiGeorge Syndrome; Fragile X Syndrome | Details |
| Adezunap | AP-707 | Phase 3 Clinical | CannaXan GmbH | Accidental Injuries; Back Pain; Brachial Plexus Neuropathies; Brain Injuries, Traumatic; Chronic Pain; Diabetes Mellitus; Diabetic Neuropathies; Diabetic peripheral neuropathy; Low Back Pain; Multiple Sclerosis; Neuralgia; Pain; Pain, Postoperative; Paraplegia; Peripheral Nerve Injuries; Peripheral Nervous System Diseases; Phantom Limb; Somatoform Disorders; Stroke | Details |
| Dronabinol（Vertanical） | VER-01 | Phase 3 Clinical | Vertanical GmbH | Low Back Pain | Details |
| cannabidiol (Cardiol Therapeutics) | Phase 3 Clinical | Cardiol Therapeutics Inc | Cardiovascular Diseases; Coronavirus Disease 2019 (COVID-19); Myocarditis; Pericarditis | Details | |
| Selonabant | V-24343; ANEB-001; VER-24343 | Phase 2 Clinical | Vernalis Plc | Obesity; Poisoning | Details |
| 11C-MePPEP | 11C-MePPEP | Phase 2 Clinical | Eli Lilly And Company | Obesity; Substance-Related Disorders | Details |
| AX-1602 | AX-1602 | Phase 2 Clinical | Axim Biotechnologies Inc | Dermatitis, Atopic; Psoriasis; Vitiligo | Details |
| Nimacimab | RYI-018; RYI-028; JNJ-2463 | Phase 2 Clinical | Bird Rock Bio Inc | Diabetic Gastroparesis; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Renal Insufficiency, Chronic | Details |
| ART-2713 | NEO-1940; ART-2713; ART27.13; AZD-1940 | Phase 2 Clinical | Astrazeneca Plc, Neomed Inc, Pfizer Inc | Anorexia; Cachexia; Low Back Pain; Pain; Weight Loss | Details |
| AEF-0217 | AEF-0217 | Phase 2 Clinical | Aelis Farma | Down Syndrome | Details |
| Monlunabant | S-MRI-1891; (-)-MRI-1891; NN9440–INV-202; INV-202; MRI-1891 | Phase 2 Clinical | Inversago Pharma Inc | Diabetic Nephropathies; Metabolic Diseases; Metabolic Syndrome; Obesity | Details |
| Cannabidiol (Ananda Scientific) | A-1002-N5S; A1002N5S | Phase 2 Clinical | Ananda Scientific Inc | Chronic Pain; Opioid-Related Disorders; Stress Disorders, Post-Traumatic; Tobacco Smoking; Tobacco Use Disorder | Details |
| Cannabidiol (Biopharmaceutical Research Company) | BRC-001 | Phase 2 Clinical | Biopharmaceutical Research Company | Breast Neoplasms; Carcinoma, Ductal, Breast | Details |
| C20T5 | C20T5 | Phase 2 Clinical | Murdoch Childrens Research Institute | Details | |
| C12T12 | C12T12 | Phase 2 Clinical | Murdoch Childrens Research Institute | Details | |
| Suvadronabinol | THC-VHS-NEC; SBI-100; NB-1111; Sb-100 OE; SBI-100 OE; THCVHS; THCVHS-N; THCVHS-NE; UM-5050 | Phase 2 Clinical | University Of Mississippi | Glaucoma; Glaucoma, Open-Angle; Ocular Hypertension | Details |
| IGC-AD1 | IGC-AD1 | Phase 2 Clinical | University Of South Florida | Alzheimer Disease; Dementia; Psychomotor Agitation | Details |
| Lixosicone | AEF-0117 | Phase 2 Clinical | Aelis Farma, National Institute On Drug Abuse | Marijuana Abuse | Details |
| ZYN-001 | ZYN-001 | Phase 1 Clinical | Zynerba Pharmaceuticals | Fibromyalgia; Neuralgia | Details |
| Tetrahydrocannabivarin | GWP-42004; THCV; O-4394; DELTA9-THCV; GW-42004 | Phase 1 Clinical | Gw Pharmaceuticals Plc | Diabetes Mellitus, Type 2; Dyslipidemias; Hypercholesterolemia; Hyperglycemia; Metabolic Syndrome; Obesity, Morbid | Details |
| Cannabidiol/hydroxychloroquine | IHL-675A; IHL-675 | Phase 1 Clinical | Incannex Healthcare Ltd | Arthritis, Rheumatoid; Respiratory Distress Syndrome, Adult | Details |
| Zevaquenabant | MRI-1867; (S)-MRI-1867; INV-101 | Phase 1 Clinical | National Institutes Of Health | Scleroderma, Systemic | Details |
| Cannabidiol (Artelo Biosciences) | ART-12.11; ART12.11; ART-1211 | Phase 1 Clinical | Artelo Biosciences Inc | Anxiety; Depression; Depressive Disorder | Details |
| S1-221 | S1-221 | Phase 1 Clinical | Delphian Therapeutics Australia Pty Ltd | Details | |
| Cannabidiol (Tiamat Australia) | MRX-1 | Phase 1 Clinical | Tiamat Australia Pty Ltd | Details | |
| Atorvastatin Calcium Hydrate/Cannabidiol | Phase 1 Clinical | Indication Bioscience LLC | Coronary Disease; Dyslipidemias | Details | |
| TPT0301 | TPT-0301; TPT0301 | Phase 1 Clinical | Tetra Pharm Technologies ApS | Chronic Pain | Details |
| INV-347 | NN9441; NN-9441; INV-347 | Phase 1 Clinical | Inversago Pharma Inc | Obesity | Details |
| IPI 201（Isosceles Pharmaceuticals Inc ） | IPI-201 | Phase 1 Clinical | Pain, Postoperative | Details | |
| CRB-913 | CRB-913 | Phase 1 Clinical | Jenrin Discovery LLC | Obesity | Details |
| GFB-024 | Phase 1 Clinical | Takeda Pharma | Diabetes Complications; Diabetes Mellitus; Diabetic Nephropathies; Endocrine System Diseases; Kidney Diseases | Details | |
| DBPR-211 | Phase 1 Clinical | National Health Research Institutes | Diabetes Mellitus, Type 2 | Details | |
| MP-10X | MP-10X | Clinical | Medipure Holdings | Pain | Details |
| MP-20X | MP-20X | Clinical | Medipure Holdings | Anxiety Disorders; Mood Disorders | Details |
| Cannabidiol (Receptor Life Sciences) | Clinical | Receptor Life Sciences Inc | Autism Spectrum Disorder | Details | |
| Cannabidiol/Palmitoylethanolamide | SCI–210; THX-210 | Clinical | Therapix Biosciences Ltd | Autism Spectrum Disorder; Diabetic Neuropathies | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Cannabidiol/Dronabinol | delta-9-THC/CBD; MPL-001; MPL-005; PPP-011; BOL-DP-o-04; GW-1000-02; PPP-001; MGC-ODT; GW-1000; KL16-012; THC-5 | Approved | Gw Pharmaceuticals | Sativex, Qixleef, QIXLEEFTM | Canada | Cancer Pain; Chronic Pain; Muscle Spasticity; Neuralgia; Multiple Sclerosis | null | 2005-04-01 | Acute Pain; Agitation; Agoraphobia; Anorexia; Anxiety Disorders; Arthritis, Psoriatic; Arthritis, Rheumatoid; Back Pain; Cancer Pain; Cerebral Palsy; Chronic Pain; Corticobasal degeneration; Dementia; Depression; Depressive Disorder, Major; Diabetic Neuropathies; Drug Resistant Epilepsy; Essential Tremor; Genital Diseases, Male; Healthy Aging; Hepatic Insufficiency; Hidradenitis Suppurativa; Huntington Disease; Kidney Diseases; Low Back Pain; Malnutrition; Marijuana Abuse; Marijuana Use; Migraine Disorders; Multiple Sclerosis; Muscle Spasticity; Neck Pain; Neoplasms; Neuralgia; Neuralgia, Postherpetic; Neuromyelitis Optica; Opioid-Related Disorders; Osteoarthritis, Knee; Pain; Panic Disorder; Peripheral Nervous System Diseases; Phobia, Social; Psoriasis; Reflex Sympathetic Dystrophy; Renal Insufficiency; Renal Insufficiency, Chronic; Sciatica; Sleep Initiation and Maintenance Disorders; Sleep Wake Disorders; Social Behavior; Spasm; Spinal Cord Injuries; Squamous Cell Carcinoma of Head and Neck; Stress Disorde | Details |
| Cannabidiol | CHI-902; APH-1501; GLA-015; BTX-1503; BTX-1801; GWP-42003-P; BOL-DP-o-05; GW-42003; BTX-1204; PTL-101; BTX-1702; PBX-1308; BRCX-014; LYT-310; GWP-42003 | Approved | Gw Pharmaceuticals Plc | Epidyolex, Cannepil, Epidiolex | United States | Epilepsies, Myoclonic; Lennox Gastaut Syndrome | null | 2018-06-25 | Acne Vulgaris; Acute Pain; Alcohol Abstinence; Alcoholic Intoxication; Alcoholism; Anemia, Sickle Cell; Anorexia Nervosa; Anxiety; Anxiety Disorders; Appetitive Behavior; Arthralgia; Arthritis, Psoriatic; Arthritis, Rheumatoid; Autism Spectrum Disorder; Autistic Disorder; Azotemia; Behavior, Addictive; Bipolar Disorder; Blepharospasm; Brain Diseases; Brain Injuries, Traumatic; Breast Neoplasms; Bruxism; Burnout, Psychological; Cachexia; Carcinoma, Non-Small-Cell Lung; Carpal Tunnel Syndrome; Central Nervous System Diseases; Child Behavior Disorders; Chronic Pain; Chronic Periodontitis; Chronic Urticaria; Cicatrix; Cognition Disorders; Cognitive Dysfunction; Colitis, Ulcerative; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Corticobasal degeneration; Craving; Crohn Disease; Cystitis, Interstitial; Dentin Sensitivity; Depression; Dermatitis, Atopic; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Driving Under the Influence; Drug Resistant Epilepsy; Dyslipidemias; Dysmenorrhea; Dyspepsia; Eczema; | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information